Clinical Disease Monitoring
Clinical Disease Monitoring - Related Videos
15:09
The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
0 Views •
Cited by 22 •
2012
Fibroblasts from patients carrying mutations in Parkinson's disease-causing genes represent an easily accessible ex vivo model to study disease-associated phenotypes. Live cell imaging gives the opportunity to study morphological and functional parameters in living cells. Here we describe the preparation of human fibroblasts and subsequent monitoring of mitochondrial phenotypes.
07:35
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
0 Views •
Cited by 14 •
2015
The use of ultra-high field MRI as a non-invasive way to obtain phenotypic information of rodent models for polycystic kidney disease and to monitor interventions is described. Compared with the traditional histological approach, MRI images can be acquired in vivo, allowing for longitudinal follow-up.
09:09
In Silico Clinical Trials for Cardiovascular Disease
0 Views •
Cited by 3 •
2022
This protocol demonstrates the workflow of the SILICOFCM platform for automatically generating a parametric model of the left ventricle from patient-specific ultrasound images by applying a multi-scale electromechanical model of the heart. This platform enables in silico clinical trials intended to reduce real clinical trials and maximize positive therapeutic outcomes.
01:24
Chronic Kidney Disease II: Clinical Manifestations
0 Views •
2025
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:30
Coronary Artery Disease III: Clinical Manifestations
0 Views •
2025
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
FAQs
Meaningful change emerges from trends across repeated measurements rather than from one result alone. Clinicians can compare symptoms and other clinical findings with pathogen detection, antibody or antigen results, inflammatory markers, and immune-cell analysis at different time points. Concordant or discordant patterns help indicate whether disease is improving, persisting, recurring, or progressing.
Each measurement captures a different part of the disease process. Pathogen tests provide information about the infectious agent, while antibody or antigen testing and immune-cell analysis reflect aspects of host response; inflammatory markers add evidence of immune activation. Combining these data with clinical findings gives monitoring a broader basis for interpreting treatment response and disease risk.
Treatment decisions depend on how monitored findings change after therapy begins. Improvement across clinical and laboratory measures can support continued management, whereas persistent abnormalities or renewed changes may signal inadequate control, relapse, or progression. The same framework can guide antimicrobial treatment and immune-directed treatment while helping identify safety concerns during ongoing care.
A practical workflow starts with systematic collection of clinical findings and selected laboratory measurements, followed by comparison with results from earlier time points. Interpretation can incorporate pathogen detection, antibody or antigen testing, inflammatory markers, and immune-cell analysis as relevant to the disease. Repeating this process creates a time-based record for recognizing meaningful change.
Standardization makes findings more consistently comparable across repeated time points. An organized set of clinical and laboratory observations supports surveillance, improves recognition of treatment-related safety issues, and gives researchers a clearer way to evaluate host responses and clinical outcomes. It also strengthens the evidence used to develop more precise strategies for managing infectious and immune-mediated disease.
In infectious disease care, serial monitoring can support early recognition of infection or relapse by linking clinical findings with pathogen-related and host-response measurements. In immune-mediated disease, immune-cell analysis, inflammatory markers, and antibody or antigen results can add context to clinical changes. Across both settings, these data help connect biological responses with outcomes and treatment planning.